| NCT ID | NCT05704530 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Esophageal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 248 participants |
| Start Date | 2023-03-29 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 248 participants in total. It began in 2023-03-29 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Purpose of this study is to determine the value of liquid biopsies, e.g. testing of minimal residual disease (MRD) by using liquid biopsies to measure circulating tumour DNA (ctDNA) at diagnosis and during the multimodal and multidisciplinary curative-intent treatment of resectable esophageal cancer.
Eligibility Criteria
Key inclusion criteria are: 1. Male or female, age \> 18 years 2. New diagnosis of esophageal cancer, pathologically confirmed squamous cell carcinoma (ESCC) or adenocarcinoma (EAC) 3. Clinically staged - cT1-4 N0-2 M0 (local or locally advanced, resectable) 4. Eligible for multidisciplinary treatment as assessed by MDT 5. Able to provide informed consent (ICF) according to Good Clinical Practice and national/European regulations Key exclusion criteria are: 1. (Oligo)metastatic disease 2. Histologically or cytologically confirmed diagnosis other than squamous cell carcinoma or adenocarcinoma (eg. neuroendocrine carcinoma, lymphoma…) 3. Other active malignancies 4. Previous exposure to chemoradiation (prior to MDT) 5. Treatment plan after MDT: neoadjuvant chemotherapy with no radiation or chemoradiation with definitive intent (surgery is not planned)
Contact & Investigator
Jeroen Dekervel, MD
PRINCIPAL INVESTIGATOR
Universitaire Ziekenhuizen KU Leuven
Frequently Asked Questions
Who can join the NCT05704530 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Esophageal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05704530 currently recruiting?
Yes, NCT05704530 is actively recruiting participants. Contact the research team at jeroen.dekervel@uzleuven.be for enrollment information.
Where is the NCT05704530 trial being conducted?
This trial is being conducted at Antwerp, Belgium, Ghent, Belgium, Leuven, Belgium, Roeselare, Belgium.
Who is sponsoring the NCT05704530 clinical trial?
NCT05704530 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Jeroen Dekervel, MD at Universitaire Ziekenhuizen KU Leuven. The trial plans to enroll 248 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.